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Abstract. internalisation and recycling of seven trans-
membrane domain receptors is a critical regulatory event for 
their signalling. The mechanism(s) by which membrane 
progesterone receptor-α (mPrα) number is regulated on the 
cell surface is unclear. in this study, we investigated the cellular 
distribution of mPrα and mechanisms of mPrα trafficking 
using a cell line derived from a primary culture of human 
myometrial cells (M11) as an experimental model. rT-Pcr 
and immunofluorescent analysis demonstrated expression of 
mPrα in M11 cells with mPrα primarily distributed on the 
cell surface under basal conditions. For the first time, plasma 
membrane localisation of mPrα was confirmed using immuno-
gold transmission electron microscopy. Stimulation of M11 
cells with progesterone (P4, 100 nM) resulted in internalisation 
of mPrα from the plasma membrane to the cytoplasm 
(10 min) and subsequent limited translocation back to the 
cell surface (20 min). We investigated potential endocytotic 
pathways involved in trafficking of mPRα after its internali-
sation. Partial co-localisation of clathrin with mPrα was 
obvious after 10 min of P4 treatment. of note, chlorpromazine 
(inhibitor of clathrin-mediated pathway) inhibited the endo-
cytosis of mPrα, whereas treatment with nystatin (inhibitor 
of caveolae-mediated pathway) did not affect internalisation. 
collectively, these data suggest that mPrα is expressed on the 
cell surface of M11 cells and undergoes endocytosis after P4 
stimulation primarily via a clathrin-mediated pathway.
Introduction
The large group of seven transmembrane domain receptors 
(7TMRs) include the well-known superfamily of G protein 
coupled receptors (GPCRs) as well as the phylogenetically 
distinct family of membrane progesterone receptors (mPrs) 
(1,2). Trafficking of 7TMRs between the various cell com-
partments is crucial for their ligand-binding and signalling 
functions. internalisation of 7TMrs by endocytosis controls 
important receptor functions in the cell, fine tuning the binding 
characteristics of the receptor and regulating the activation 
of different signal transduction pathways. Some cell-surface 
receptors can also activate signal transduction pathways from 
intracellular compartments, suggesting that signalling can be 
regulated by compartmentalization (3).
Internalisation of many GPCRs involves rapid clathrin-
mediated endocytosis (3-5). The agonist-occupied receptor 
is recruited into clathrin-coated pits (ccP), which then form 
vesicles for entry into the endocytic pathway. at this stage, 
vesicles and their cargo can be directed for either degrada-
tion or recycling back to the cell surface (6,7). For example, 
it has been shown that different internalisation routes seem to 
predetermine whether transforming growth factor β (TGF-β) 
receptors will trigger a signalling response or be degraded 
(3). The precise mechanisms influencing the fate of the CCP-
receptor complex are not fully elucidated, but emerging data 
suggest that they are receptor specific and may vary between 
cell types (8). Another route by which GPCRs can be interna-
lised involves caveolae and is independent of clathrin-coated 
pits (4,7). To date, nothing is known about the internalisation 
of another family of 7TMrs, the mPrs.
The mPRs were initially discovered in a teleost fish. More 
than 20 closely related genes have been cloned from other 
vertebrate species, including 3 mPr subtypes in humans, 
named α, β and γ, which show high levels of expression in 
human reproductive, brain and kidney tissues, respectively 
(1,2). recently, ligand binding of another two members of the 
mPr family, named mPrδ and mPrε, has been characterised 
(9). Structural analyses of the translated cdnas suggest that 
they encode membrane proteins with seven transmembrane 
domains. Thomas et al have shown that mPrα is a membrane-
bound progestin receptor that activates G proteins, despite 
having a different ancestral origin to GPCRs (10). Karteris 
and co-workers have also shown that mPRα is expressed 
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on myometrial cells and couples to inhibitory G proteins, 
resulting in an increased phosphorylation of myosin light 
chain (11). However, regulation of mPrα at the cell surface 
remains unclear, since there is a debate regarding the cellular 
distribution of these receptors. Therefore, in the present study 
we investigated the localisation of mPrα in M11 cells and 
potential endocytotic pathways involved in mPrα trafficking.
Materials and methods
Tissue culture. M11 cells were obtained from John a. copland 
(Mayo Clinic College of Medicine, Jacksonville, Fl, uSA). 
These cells were derived from dispersed human myometrial 
cells by repeated passage without the use of any immortalising 
or transforming agents. M11 cells were maintained in 
dulbecco's modified eagle's medium (dMeM) high glucose 
(with d-Valine) supplemented with 10% fetal bovine serum 
(FbS), 50 u penicillin and 50 µg streptomycin (Invitrogen, 
uK) and cultured at 37˚C in 5% Co2.
RNA isolation, cDNA synthesis and RT-PCR. Total rna was 
extracted using an RnA extraction kit (Sigma-Aldrich, uK) 
and treated with dnase i according to the manufacturer's 
instructions. rna concentration was determined by 
spectrophotometric analysis (nanodrop; Thermo Scientific, 
uK) and agarose gel electrophoresis. RnA (100 ng) was 
reverse-transcribed into cdnA using 5 Iu/µl Rnase H reverse 
transcriptase (Invitrogen). PCR amplification was carried out 
using Taq polymerase (invitrogen) and oligonucleotide primers 
(invitrogen) for human mPrα (Acc. AF313620). The primers 
for mPrα were forward 5'-GCTGTTCACTCACATCCC-3' 
and reverse 5'-TGGTGCAACCCCCAGA-3', resulting in a 
289-bp Pcr product. The primers for clathrin (138 bp) were 
forward 5'-TTAGCCGGTGCTGAAGAACT-3' and reverse 
5'-CTGGAACCGACGGA TAGTGT-3'. The primers for β-actin 
(216 bp) were forward 5'-AAGAGAGGCATCCTCACCCT-3' 
and reverse 5'-TACATGGCTGGGGTGTTGAA-3'. Thirty-
three cycles for mPrα and 28 cycles for clathrin and β-actin 
were performed, consisting of an initial denaturing step at 
94˚C for 30 sec followed by extension at 60˚C for 1 min and 
elongation at 72˚C for 1 min.
Treatment of M11 cells with progesterone (P4). Prior to 
P4 treatments, M11 cells were cultured in phenol red-free 
dMeM containing 2.5% charcoal-stripped FbS, penicillin 
and streptomycin, and incubated at 37˚C in 5% Co2 for 24 h. 
cells were exposed to 100 nM P4 for 0 (nS, unstimulated), 
10 and 20 min.
Indirect immunofluorescence analyses using mPRα antibody. 
M11 cells were fixed in 4% paraformaldehyde for 10 min 
prior to washes in PbS and permeabilization with 0.2% 
Tween-20 for 20 min. After subsequent washes in PbS, 
samples were blocked for 1 h at room temperature using 10% 
bovine serum in PbS. Fixed M11 cells were then incubated 
with a 1:100 dilution of mPrα (hmPrα, 836-4) antibody in 
1.5% bovine serum PbS overnight at 4˚C. The following day, 
preparations were washed with PbS prior to incubation with 
a 1:100 dilution of anti-rabbit IgG-fluorescein isothiocyanate 
(FITC)-conjugated antibody (Santa Cruz biotechnology, 
uSA) for 1 h. Sample preparations were washed with PbS 
and mounted in Vectashield® Mounting Medium (Vector labs) 
containing the dnA-specific dye 4,6-diamido-2-phenylindole 
(daPi) to counterstain nuclei. Preparations were incubated 
with only secondary antibody as a negative control. images 
were captured using a Plan Apo neofluor x63 nA 1.25 oil 
objective (Zeiss; Carl Zeiss International) on a Zeiss Axiovert 
200M microscope, and viewed using axioVision software 
(Zeiss; Carl Zeiss International). Images were collected at set 
exposure times of 3000 msec, with the exception of the nuclei 
counterstained with daPi, which were collected under an 
automatic exposure time.
Dual-indirect immunofluorescence using mPRα and clathrin 
antibodies. The general indirect immunofluorescence protocol 
described previously was adhered to, with several modifications. 
Samples were blocked for 1 h at room temperature in 10% 
bovine serum and 10% donkey serum in PbS. Preparations 
were incubated at 4˚C overnight in a 1:100 dilution of mPRα 
(hmPrα, 836-4) antibody and a 1:200 dilution of anti-clathrin 
heavy chain antibody (Abcam, uK) respectively diluted with 
1.5% bovine serum and 1.5% donkey serum in PbS. The 
secondary antibody incubation consisted of a 1:100 dilution 
of anti-rabbit IgG-FITC antibody and a 1:100 dilution of 
anti-goat IgG rhodamine antibody (both from Santa Cruz 
biotechnology, uSA) respectively composed with 3% bovine 
serum and 3% donkey serum in PbS for 1 h.
Treatment of M11 cells with endocytosis inhibitors. The dual-
indirect immunofluorescence protocol described previously 
using antibodies directed against mPrα and clathrin was used 
on M11 cells treated with the following inhibitors for various 
endocytotic pathways: chlorpromazine, dansylcadverine, 
nystatin and sucrose. M11 cells were cultured in phenol red-free 
dMeM containing 2.5% charcoal-stripped serum, penicillin 
and streptomycin, and incubated at 37˚C in 5% Co2 24 h prior 
to inhibitor and P4 treatment. a negative control was prepared 
in each instance. M11 cells were incubated for 15 min at 37˚C 
with 50 µM chlorpromazine hydrochloride (Sigma-Aldrich) 
using a protocol described previously by Wang et al (12), then 
assessed under basal conditions (nS) and exposed to 100 nM 
P4 for 10 min. M11 cells were treated with 25 µg/ml nystatin 
(Sigma-Aldrich) at 37˚C for 30 min as previously described 
(13,14). cells were subsequently exposed to 100 nM P4 for 
10 min, but also treated under basal conditions (nS). M11 
cells were incubated with 0.45 M sucrose (Sigma-aldrich) at 
37˚C for 15 min, described by Heuser and Anderson at basal 
conditions and prior to P4 exposure of 10 min (15).
Protein extraction from cultured M11 cells. M11 cells were 
cultured in 6-well dishes until reaching 80% confluency  and 
maintained overnight in phenol red-free dMeM containing 
2.5% charcoal-stripped FbS, penicillin and streptomycin, 
before the addition of agonists/inhibitors. cells were lysed using 
200 µl 2X laemmli buffer (Sigma-Aldrich) and denatured for 
5 min at 100˚C.
Immunogold electron microscopy. M11 cells were grown 
to confluency on 35-mm polystyrene dishes at 37˚C in the 
presence of 5% co2 in high glucose dMeM with 10% heat-
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inactivated FbS, penicillin and streptomycin. Cells were 
washed with 0.1 M Sorensen's phosphate buffer (pH 7.0) and 
fixed in 0.1% glutaraldehyde for 30 min at room temperature. 
Cells were washed and then blocked with 10% donkey serum 
for 30 min at room temperature. anti-clathrin antibody 
(Sigma-aldrich) diluted 1:40 with Sorensen's phosphate buffer 
containing 1% donkey serum and 0.1% sodium azide was 
applied to the cells and incubated overnight at 4˚C. Washed 
cells were incubated in 18-nm gold labelled donkey anti-goat 
IgG secondary antibody, 1% donkey serum and 0.1% sodium 
azide for 1 h at room temperature. Post-fixation was performed 
in 2% glutaraldehyde for 10 min followed by fixation with 1% 
osmium tetroxide for 1 h at room temperature. The cells were 
dehydrated through a graded ethanol series and embedded 
in epoxy resin. ultrathin sections were collected on copper 
grids and stained with uranyl acetate and lead citrate prior to 
observation by transmission electron microscopy (eM) using 
a Jeol 2000 FX Transmission electron Microscope.
M11 cells were also probed with mPrα (hmPrα, 836-4) 
antibody and goat anti-rabbit IgG 10-nm gold labelled secondary 
antibody. These cells were treated using the aforementioned 
protocol with the following exceptions: firstly, cells were 
blocked in 1% bovine serum albunin (bSA), 10% goat serum; 
secondly, antibodies were diluted in 1% goat serum, 1% bSA 
and 0.1% sodium azide made up in 0.1 M Sorensen's phosphate 
buffer pH 7.0.
P4 binding. M11 cells incubated in opti-MeM (invitrogen) 
supplemented with 30 mM HePeS and 0.2% bSA were 
grown on glass bottomed Petri dishes. These were incubated 
with 100 nM progesterone 3-(o-carboxymethyl)oxime: 
bSA-fluorescein isothiocynate conjugate (Sigma-Aldrich) 
for 10 and 45 min at room temperature prior to fixation with 
4% paraformaldehyde for 10 min. after subsequent washes 
with PbS, the cells were permeabilised with 0.1% saponin, 
0.5% bSA in PbS for 20 min. Fixed cells were then washed 
with PbS and incubated with a 1:300 dilution of phalloidin-
Alexa fluor 568 (Molecular probes, uK) in 0.5% bSA PbS 
for 15 min prior to further PbS washes. The M11 cells were 
mounted with antifade solution (Citifluor-PbS, Citifluor ltd., 
uK) and visualised using a nikon eclipse Te2000S confocal 
microscope.
Figure 1. P4 binding, expression and cellular distribution of mPrα in M11 cells. (a) confocal images of M11 cells incubated with P4 3-(o-carboxymethyl)
oxime-bSA-FITC at room temperature for 20 min (I) and 45 min (II). Green represents progesterone and blue, phalloidin. (b) RT-PCR analysis for mPRα: 
lane 1, dnA ladder; lane 2, cdnA from M11 cells; lane 3, cdnA from myometrial tissue; lane 4, negative control (no cdnA input). (C) Immunofluorescent 
analysis for mPrα in an M11 cell showing the distribution of mPrα (green) across the cell membrane. The nucleus was counterstained with dAPI (blue) (I); 
II is the negative control. Scale bar, 10 µm. (d) mPRα localisation and the cellular morphology of M11 cells using TeM. M11 cells had intact cytoplasmic 
machinery and a distinct cell membrane (I). Immunogold electron microscopy revealed mPRα localisation and distribution detected via a secondary antibody 
conjugated to 10-nm gold beads. This revealed specific staining on the cell membrane (indicated by black arrows, II and III) and within the cytoplasm (indicated 
by white arrow, iii). iV is a control preparation depicting the size of the 10-nm gold beads conjugated to the anti-rabbit secondary antibody used in these 
preparations. Scale bar, 100 nm, with the exception of i, 250 nm.
  A
  B
  D
  C
FoSTer et al:  inTernaliSaTion oF mPrα30
Statistical analysis. expression mPrα protein was determined 
using Western blot analysis as described previously (11) and 
with semi-quantitative densitometry performed using niH 
ImageJ (v1.26).
Results
Membrane binding of progesterone, expression and cellular 
distribution of mPRα in M11 cells. Membrane progesterone 
sites were detected in M11 cells upon incubation with P4 
3-(o-carboxymethyl)oxime-bSA-FITC at room temperature 
for 20 min (Fig. 1a, panel i) and 45 min (Fig. 1a, panel ii).
expression of mPrα at the gene level was confirmed in M11 
cells via RT-PCR (Fig. 1b). Furthermore, mPRα expression 
was verified at the protein level through indirect immuno-
fluorescence (Fig. 1C) and immunogold electron microscopy 
(Fig. 1d), both of which depict characteristic plasma mem-
brane localisation in M11 cells under basal conditions.
electron microscopy is the gold standard and the most 
robust technique for determining the cellular distribution of 
mPrα within M11 cells. using this technique, we verified 
that M11 cells have an intracellular environment rich in the 
mandatory organelles essential for transcription and transla-
tion processes (Fig. 1d, panel i). immunogold eM provided 
Figure 2. distribution of mPrα in M11 cells upon stimulation with P4. under basal conditions (nS), mPrα was predominantly confined to the cell surface. 
after 10 min of treatment with 100 nM P4, translocation of mPrα from the cell surface towards the cytoplasm was evident. However, after exposure to P4 for 
20 min, a substantial amount of mPrα protein was localised back at the plasma membrane. Scale bar, 10 µm. -ve CTRl, negative control immunostaining with 
secondary antibody only.
Figure 3. Western blot analysis of mPrα protein M11 plasma membranes after 
exposure to P4 for a 1-, 15- and 30-min duration. (a) M11 plasma membrane 
preparations (P4 100 nM for 1, 15 and 30 min) probed with an mPrα anti-
body resulting in 80 kda bands. (b) Immunoblotting with a cadherin antibody 
shows equal membrane protein loading on the gel for each time point. (c) 
Semi-quantification of mPRα protein on M11 plasma membrane samples by 
the normalisation of mPrα protein with cadherin protein and semi-quantitative 
densitometry performed using nIH ImageJ (v1.26). Statistical differences were 
determined for each of the different P4 exposure times (***P<0.001 compared 
with 1 min; +++P<0.001 compared with 1 and 15 min; one way AnoVA).
  A
  B
  C
Molecular Medicine rePorTS  3:  27-35,  2010 31
irrefutable evidence for the first time that mPRα occupies a 
location at the cell membrane in M11 cells under basal condi-
tions (Fig. 1d, panel ii). nevertheless, mPrα also occasionally 
occupied an intracellular locality within the cell cytoplasm 
(Fig. 1d, panel iii).
Sequestration and trafficking of mPRα from the plasma 
membrane after P4 stimulation. To study the potential 
trafficking of mPRα and to further determine its distribution 
pattern, immunofluorescent analyses were conducted in 
M11 cells treated with P4 (100 nM) for 5, 10 and 20 min. in 
untreated cells, mPrα was localised both at the cell surface 
and cytoplasm (Fig. 2; nS). Following 5 min of P4 treatment, 
there was an altered distribution of the receptor with mPrα 
present both on the cell membrane and in the cytoplasm (data 
not shown). at 10 min of treatment, there was a clear decline 
in mPrα localised to the cell membrane (Fig. 2; 10 min), 
whereas at 20 min the receptor was again detected on the 
plasma membrane (Fig. 2; 20 min).
To confirm trafficking of mPRα following progesterone 
treatment, solubilised M11 plasma membrane preparations 
treated with 100 nM P4 for 1, 15 and 30 min (Fig. 3a) were 
subjected to Western blot analysis with mPrα specific anti-
bodies. Plasma membrane levels of mPrα protein varied with 
the duration of P4 exposure. The highest level of mPrα protein 
was present at the membrane after a 1-min exposure to P4, with 
a subsequent reduction in levels at 15 min of treatment and an 
increase at 30 min. Western blot analysis using an antibody 
directed against cadherin (Fig. 3b), a transmembrane protein 
involved in cell adhesion, was used as a control to normalise 
mPrα protein levels in the plasma membrane (Fig. 3b). 
normalised mPrα/cadherin levels showed a significant dif-
ference (P<0.001) when comparing protein from the 15-min 
P4 exposure to the 1-min exposure, with a reduction in mPrα 
present at the plasma membrane at 15 min. A significant dif-
ference (P<0.001) in mPrα protein levels also occurred when 
comparing the 30-min P4 exposure to the 1- and 15-min P4 
exposures, with 30-min P4 levels being statistically lower than 
the 1-min levels, but higher than the 15-min levels (Fig. 3c). 
These data support the hypothesis that mPrα is expressed on 
the cell membrane, rapidly internalised after stimulation with 
P4, and then recycled/shuttled back to the plasma membrane.
Expression and distribution of clathrin in M11 cells. as men-
tioned previously, a major mechanism for the internalisation of 
GPCRs is via clathrin-mediated endocytosis. Therefore, in order 
to investigate the potential involvement of clathrin in the endo-
cytosis of mPrα, we characterised its expression and trafficking 
in M11 cells. Semi-quantitative rT-Pcr analysis revealed that, 
firstly, clathrin mRnA is expressed in M11 cells, and, secondly, 
that its expression remains unaltered with up to 30 min of P4 
treatment (Fig. 4a). immunogold eM was also used to reveal 
that there are distinct changes in the distribution of clathrin in 
P4-stimulated M11 cells. after 10 min of P4 treatment, there 
was a change in clathrin distribution, with a noticeable increase 
in cluster sequestration (Fig. 4b, panel II; 10 min compared to 
panel I; nS). At 20 min of P4 treatment, there was a distinct 
internalisation of clathrin in the cytoplasm, with some remaining 
on the plasma membrane (Fig. 4b, panel III; 20 min).
Co-distribution of mPRα with clathrin. under basal condi-
tions, clathrin was distributed throughout the cell (Fig. 5A; 
nS), whereas mPrα was predominantly limited to the plasma 
membrane. little colocalisation between clathrin and mPrα 
Figure 4. expression of clathrin in M11 cells and its cellular distribution. (a) rT-Pcr analysis for clathrin and β-actin in P4-treated M11 samples. lane 1, dna 
ladder; lane 2, nS; lanes 3-9, cdnA from M11 cells treated with P4 for 1, 3, 5, 10, 15, 20 and 30 min respectively; lane 10, negative control. (b) Immunogold 
electron microscopy illustrating the localisation and distribution of clathrin in M11 cells detected via a secondary antibody conjugated to 18 nm gold beads. This 
revealed clathrin (arrows) to be dispersed in non-P4-treated M11 cells (i). after exposure to P4 for 10 min, clathrin appeared to form clusters (ii). at 20 min of 
P4 treatment, clathrin was present both on the cell membrane and internalised within the cytoplasm (iii). iV, negative control. Scale bar, 100 nm.
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Figure 5. colocalisation of mPrα and clathrin in P4-treated M11 cells. The immunofluorescent images depict the distribution and partial colocalisation of 
mPrα (green) and clathrin (orange) in M11 cells. nuclei were counterstained with daPi (blue). clathrin and mPrα colocalisation was determined in M11 cells 
after treatment with P4 for 10 and 20 min. Scale bar, 10 µM.
Figure 6. effect of inhibitors on clathrin and mPRα endocytosis in M11 cells. M11 cells were exposed to P4 for 10 min prior to treatment with specific inhibi-
tors to determine how this influences clathrin and mPRα endocytosis. The immunofluorescent images depict clathrin (orange) and mPRα (green) treated with 
chlorpromazine, nystatin or sucrose. Scale bar, 10 µM.
Molecular Medicine rePorTS  3:  27-35,  2010 33
was evident (Fig. 5A; nS). At 10 min of P4 exposure, both 
clathrin and mPrα were increasingly localised within the 
cell (Fig. 5A; 10 min). Partial colocalisation between mPRα 
and clathrin was determined, visible in the merged image as 
orange-coloured speckles (Fig. 5A; 10 min). The distribution 
of both mPrα and clathrin at 20 min of P4 treatment seem-
ingly reverted to that observed under basal conditions (Fig. 5A; 
20 min).
Use of endocytotic inhibitors to investigate potential 
internalisation pathways of mPRα. at 10 min of P4 exposure, 
internalisation and partial colocalisation of mPrα and clathrin 
was evident in the M11 cells (Fig. 5A; 10 min). Inhibitors of 
endocytosis were used on M11 cells, which were then exposed 
to 10 min of P4 treatment to examine the resultant distribution 
and colocalisation properties of clathrin and mPrα. Treatment 
of M11 cells with chlorpromazine resulted in an atypical clathrin 
distribution, with a reduction in observed clathrin speckles 
(Fig. 6; chlorpromazine). mPRα appeared to be sequestered 
in much larger, but fewer, clusters localised at either the cell 
membrane or the cellular interior (Fig. 6; chlorpromazine). no 
clear colocalisation between clathrin and mPrα was apparent 
(Fig. 6; chlorpromazine). nystatin inhibitor did not alter the 
clathrin or mPrα distribution, nor their partial colocalisation, 
which is readily observed under standard conditions (Fig. 
6; nystatin). Sucrose treatment of M11 cells altered mPRα 
distribution (Fig. 6; sucrose). The internal clustering of mPRα 
typically seen in M11 cells was also less apparent, with no 
observable internal sequestration of mPrα (Fig. 6; sucrose). 
clathrin and mPrα did not appear to colocalise when treated 
with sucrose.
Discussion
in this study, we investigated the cellular distribution and 
trafficking of mPRα in a human myometrial cell line (M11). 
We chose this experimental model since it has been shown to 
have morphological characteristics typical of myometrial cells 
(16), and also expresses mPRα (11,17).
Immunofluorescent analysis revealed that mPRα has a 
similar subcellular distribution to that previously observed in 
human myometrial cells under basal conditions (11), and is 
localised on the plasma membrane, with some cytoplasmic 
expression. in agreement with these results, membrane locali-
sation of  mPrs has been demonstrated by several research 
groups in a variety of cell types (1,10,18-22). other researchers 
have reported mPrs to be localised intracellularlly in the 
endoplasmic reticulum (23-25). eM is the gold standard in high 
resolution imaging, and was used to conclusively determine the 
sub-cellular distribution of mPrα. mPrα occupies a cell mem-
brane location under basal conditions, but intracellular mPrα 
is also apparent. These novel data incorporated eM for the first 
time to address mPrα distribution in any given cell type.
an important characteristic of 7TMrs is that they are 
rapidly internalised upon activation in a ligand-dependent 
manner, an event critical for their proper functioning (26). 
Currently, there is no information on the trafficking of mPRα. 
Therefore, we utilised an immunofluorescent approach to 
investigate the trafficking of mPRα. mPrα protein was re-
distributed from the cell membrane in unstimulated cells, 
becoming internalised at 10 min of P4 exposure. mPrα was 
presented back on the cell membrane at 20 min, but not to the 
levels previously seen under basal conditions. This was ligand 
specific, since treatment with the unrelated steroid cortisol 
(100 nM) and the nuclear Pr activator r5020 (30 nM) did 
not induce any significant internalisation of the receptor in 
M11 cells (data not shown). The mPrα internalisation was 
confirmed by specific single-point P4 binding studies. At 
20 min, there was a significant decrease in [3H]-P4 binding on 
the plasma membrane of M11 cells as compared with 1-min P4 
treatment (data not shown). The decrease in membrane-bound 
mPrα may act as a desensitisation process to modulate rapid 
P4 signalling responses.
These data are consistent with the data in the literature, 
which indicate that the intracellular segregation of receptors 
due to endocytotic events is a common fate for 7TMrs. This 
provides another explanation for why several 7TMrs appear 
to be expressed in the cytoplasm (27), and may also explain why 
some investigators have observed mPRs intracellularly. In kidney 
tissue, mPrα was found to be restricted to the endoplasmic 
reticulum (er) due to a c-terminal er retention motif (25). 
This is not unusual for 7TMrs, since many require accessory 
proteins to ensure transport to the plasma membrane (28,29). 
an example is the melanocortin 2 receptor, which is localised 
within the er and cannot be transported to the plasma mem-
brane unless it is co-expressed with the melanocortin 2 receptor 
accessory protein (28). it possible, therefore, that mPrα requires 
an accessory protein that is expressed in tissue- or cell-specific 
manner, thus affecting its transport to the membrane. These 
studies highlight the difficulty in drawing any firm conclusions 
on 7TMR trafficking (30), and present an arguement for a higher 
order of complexity regarding mPrα distribution.
The next step of this study was to further dissect the endo-
cytotic pathway(s) involved in mPrα trafficking. endocytosis 
of activated receptors can be mediated via caveolae/lipid raft 
mechanisms (32) and clathrin-dependent endocytosis. lipid 
rafts are sterol- and sphingolipid-rich membrane domains 
comprising caveolae subdomains involved in the endocytosis 
of various ligands (32,33). However, for most 7TMrs, endo-
cytosis is implemented via clathrin-mediated mechanisms 
involving the formation of coated pits at the cell surface that 
concentrate surface protein/cargo for internalisation (34). 
The role of clathrin in the endocytosis of mPrα in M11 
cells was investigated. Following progesterone treatment, there 
was partial co-localisation of clathrin with mPrα, evident in 
Fig. 5 as orange speckles. In addition, co-immunoprecipitation 
studies show that clathrin is immunoprecipitated with mPrα, 
indicating a close association between these two proteins and 
suggesting that they may be coupled under certain conditions 
(data not shown). M11 cells were treated with various inhibitors 
of endocytosis prior to progesterone treatment. inhibitors were 
chosen according to their ability to discriminate and inhibit 
different types of endocytotic pathways. Treatments included 
chlorpromazine and sucrose inhibitors specific for clathrin-
mediated internalisation and nystatin, which inhibits caveolae/
lipid-raft mediated endocytosis (35,36). These inhibitors do 
not demonstrate absolute selectivity between endocytotic 
pathways; nevertheless, they are commonly used to differen-
tiate trafficking routes (37). Chlorpromazine inhibitor acts by 
preventing the adapter protein aP2 from binding to clathrin-
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coated pits (12,38), whereas sucrose inhibitor acts by interfering 
with clathrin recruitment, coated pit formation and endocytosis 
(39). These inhibitors prevented the clathrin-mediated endo-
cytosis of mPrα. nystatin is a polyene antibiotic that inhibits 
caveolae/lipid raft-mediated endocytosis by the sequestration 
of cholesterol within the membrane, but does not affect 
clathrin-mediated endocytosis. nystatin pre-treatment did not 
alter the internalisation of mPrα after 10 min of P4 exposure. 
collectively, these data do not support a role for caveolae 
in the mediation of mPrα endocytosis. in line with these 
observations, 7TMrs have been found to predominantly use 
the clathrin-dependent endocytotic pathway, whereas caveolin 
and clathrin/caveolin-independent pathways appear to be used 
to a lesser extent (8,40,41). interestingly, other uncharacterised 
endocytotic pathways may be involved in receptor trafficking. 
For instance, corticotropin-releasing hormone receptors appear 
to undergo endocytosis independent of clathrin or caveolin upon 
activation by urocortin (42). it is therefore possible that mPrα 
is also capable of internalising via another route, independent 
of clathrin or caveolin.
Potential changes in the phosphorylation status of the 
receptor may also affect its trafficking dynamics. There are 
two different types of kinases that can phosphorylate GPCRs: 
i) second-messenger-dependent kinases (e.g., PKC), and 
ii) GPCR kinases (GRKs). β-arrestins have an essential role 
following receptor phosphorylation, functioning as adaptor 
molecules that link receptors to clathrin-coated pits (43-45). 
Potential phosphorylation sites of mPrα were predicted using 
the netPhosK Server. mPRα can be phosphorylated at two 
serine sites (positions 219, 229), three threonine sites (positions 
32, 57 and 232) and three tyrosine sites (positions 143, 194 
and 304). Future studies, using mutational analysis of these 
sites, will provide better insight regarding the potential role of 
mPrα phosphorylation in endocytotic events.
In summary, these data provide the first definitive evidence 
that mPrα can be localised on the plasma membrane and 
within the cytoplasm. This is particularly important given that 
receptor number on the cell surface is a fine balance between 
the rate of internalisation, recycling and new synthesis, and the 
fact that many receptors may also signal from endosomal com-
partments (3). Potential mechanisms involved in P4-mediated 
endocytosis have also been investigated, providing novel 
insight on mPr-mediated responses. Future studies should 
focus on determining mPrα degradation, recycling to the cell 
surface and activation of distinct intracellular pathways while 
internalised.
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